Neurotech Historical Balance Sheet

NTI Stock

0.07 0 4.55%

Trend analysis of Neurotech International balance sheet accounts such as Total Stockholder Equity of 1.3 M provides information on Neurotech International's total assets, liabilities, and equity, which is the actual value of Neurotech International to its prevalent stockholders. By breaking down trends over time using Neurotech International balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Neurotech International latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Neurotech International is a good buy for the upcoming year.

Neurotech International Inventory

34,578.85

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurotech International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Neurotech Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Neurotech International at a specified time, usually calculated after every quarter, six months, or one year. Neurotech International Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Neurotech International and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Neurotech currently owns. An asset can also be divided into two categories, current and non-current.

Neurotech International Balance Sheet Chart

At this time, Neurotech International's Common Stock Shares Outstanding is comparatively stable compared to the past year. Short Term Investments is likely to gain to about 10 M in 2024, whereas Total Stockholder Equity is likely to drop slightly above 1.3 M in 2024.

Total Assets Other Current Liab Total Current Liabilities Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Neurotech International assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Neurotech International books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Neurotech International balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Neurotech International are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Neurotech International obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Neurotech International are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Neurotech International's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Neurotech International current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurotech International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2020	2021	2022	2023 (projected)
Other Current Liabilities	25.4K	72.9K	57.8K	35.9K
Total Assets	5.0M	2.0M	5.3M	12.2M

Other Current Liab Total Assets

Neurotech International balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Long Term Debt	Net Receivables	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Other Assets
Total Assets		0.78	-0.28	0.89	-0.22	0.28	0.17	0.84	0.04	0.73	0.89	0.9	-0.1	-0.12	-0.41	0.99	-0.03	0.21	-0.04	0.78	0.66	0.67	-0.52	0.51	0.61	0.58
Other Current Liab	0.78		-0.41	0.57	-0.13	0.52	0.05	0.41	-0.33	0.28	0.92	0.86	0.24	-0.31	-0.6	0.72	-0.16	0.45	-0.34	0.72	0.64	0.79	-0.04	0.77	0.31	0.17
Total Current Liabilities	-0.28	-0.41		-0.41	-0.05	0.2	0.2	-0.36	0.07	0.01	-0.25	-0.23	-0.33	0.9	0.09	-0.3	0.16	-0.13	-0.31	-0.04	-0.03	-0.08	-0.26	-0.16	0.22	0.38
Total Stockholder Equity	0.89	0.57	-0.41		-0.03	-0.07	0.08	0.97	-0.04	0.71	0.63	0.61	-0.15	-0.3	-0.21	0.9	0.02	0.25	0.33	0.65	0.39	0.43	-0.59	0.36	0.31	0.48
Net Tangible Assets	-0.22	-0.13	-0.05	-0.03		-0.4	0.22	-0.1	-0.19	-0.22	-0.28	-0.36	0.0	0.04	0.41	-0.22	-0.49	0.36	0.36	-0.33	-0.29	-0.2	0.22	-0.03	-0.53	-0.13
Retained Earnings	0.28	0.52	0.2	-0.07	-0.4		-0.38	-0.15	-0.3	-0.14	0.62	0.53	-0.05	0.36	-0.47	0.19	0.36	0.26	-0.97	0.66	0.7	0.74	-0.09	0.69	0.33	0.02
Accounts Payable	0.17	0.05	0.2	0.08	0.22	-0.38		0.06	0.43	0.39	0.07	0.19	-0.03	0.08	-0.03	0.22	-0.61	-0.1	0.37	-0.27	-0.07	-0.14	0.19	-0.25	0.27	0.34
Cash	0.84	0.41	-0.36	0.97	-0.1	-0.15	0.06		0.11	0.77	0.53	0.55	-0.21	-0.22	-0.13	0.87	0.04	0.09	0.4	0.56	0.31	0.3	-0.69	0.18	0.4	0.56
Long Term Debt	0.04	-0.33	0.07	-0.04	-0.19	-0.3	0.43	0.11		0.44	-0.13	0.08	-0.04	0.11	0.51	0.13	-0.08	-0.7	0.27	-0.35	0.15	-0.19	0.07	-0.46	0.57	0.34
Net Receivables	0.73	0.28	0.01	0.71	-0.22	-0.14	0.39	0.77	0.44		0.44	0.57	-0.28	0.06	0.0	0.79	0.04	-0.38	0.32	0.34	0.31	0.17	-0.6	-0.08	0.71	0.74
Inventory	0.89	0.92	-0.25	0.63	-0.28	0.62	0.07	0.53	-0.13	0.44		0.97	0.06	-0.08	-0.57	0.84	0.0	0.34	-0.42	0.84	0.8	0.84	-0.27	0.72	0.54	0.37
Other Current Assets	0.9	0.86	-0.23	0.61	-0.36	0.53	0.19	0.55	0.08	0.57	0.97		0.04	-0.07	-0.53	0.88	-0.08	0.14	-0.34	0.72	0.76	0.75	-0.26	0.56	0.7	0.47
Other Stockholder Equity	-0.1	0.24	-0.33	-0.15	0.0	-0.05	-0.03	-0.21	-0.04	-0.28	0.06	0.04		-0.45	0.11	-0.11	-0.27	0.08	0.0	-0.12	0.0	0.02	0.43	0.08	-0.16	-0.05
Total Liab	-0.12	-0.31	0.9	-0.3	0.04	0.36	0.08	-0.22	0.11	0.06	-0.08	-0.07	-0.45		0.09	-0.14	0.12	-0.08	-0.43	0.09	0.14	0.07	-0.38	-0.06	0.35	0.47
Short Long Term Debt	-0.41	-0.6	0.09	-0.21	0.41	-0.47	-0.03	-0.13	0.51	0.0	-0.57	-0.53	0.11	0.09		-0.36	0.15	-0.41	0.38	-0.48	-0.15	-0.39	0.11	-0.41	-0.18	0.01
Total Current Assets	0.99	0.72	-0.3	0.9	-0.22	0.19	0.22	0.87	0.13	0.79	0.84	0.88	-0.11	-0.14	-0.36		-0.06	0.12	0.05	0.71	0.6	0.59	-0.52	0.41	0.64	0.61
Short Term Debt	-0.03	-0.16	0.16	0.02	-0.49	0.36	-0.61	0.04	-0.08	0.04	0.0	-0.08	-0.27	0.12	0.15	-0.06		-0.2	-0.33	0.38	0.28	0.15	-0.36	0.13	-0.01	-0.14
Intangible Assets	0.21	0.45	-0.13	0.25	0.36	0.26	-0.1	0.09	-0.7	-0.38	0.34	0.14	0.08	-0.08	-0.41	0.12	-0.2		-0.19	0.47	0.2	0.48	0.01	0.69	-0.4	-0.15
Common Stock	-0.04	-0.34	-0.31	0.33	0.36	-0.97	0.37	0.4	0.27	0.32	-0.42	-0.34	0.0	-0.43	0.38	0.05	-0.33	-0.19		-0.46	-0.57	-0.59	-0.07	-0.56	-0.24	0.09
Property Plant Equipment	0.78	0.72	-0.04	0.65	-0.33	0.66	-0.27	0.56	-0.35	0.34	0.84	0.72	-0.12	0.09	-0.48	0.71	0.38	0.47	-0.46		0.75	0.84	-0.56	0.78	0.36	0.36
Short Long Term Debt Total	0.66	0.64	-0.03	0.39	-0.29	0.7	-0.07	0.31	0.15	0.31	0.8	0.76	0.0	0.14	-0.15	0.6	0.28	0.2	-0.57	0.75		0.91	-0.15	0.76	0.58	0.3
Property Plant And Equipment Net	0.67	0.79	-0.08	0.43	-0.2	0.74	-0.14	0.3	-0.19	0.17	0.84	0.75	0.02	0.07	-0.39	0.59	0.15	0.48	-0.59	0.84	0.91		-0.13	0.94	0.43	0.21
Net Debt	-0.52	-0.04	-0.26	-0.59	0.22	-0.09	0.19	-0.69	0.07	-0.6	-0.27	-0.26	0.43	-0.38	0.11	-0.52	-0.36	0.01	-0.07	-0.56	-0.15	-0.13		0.0	-0.38	-0.69
Non Current Assets Total	0.51	0.77	-0.16	0.36	-0.03	0.69	-0.25	0.18	-0.46	-0.08	0.72	0.56	0.08	-0.06	-0.41	0.41	0.13	0.69	-0.56	0.78	0.76	0.94	0.0		0.09	-0.03
Non Currrent Assets Other	0.61	0.31	0.22	0.31	-0.53	0.33	0.27	0.4	0.57	0.71	0.54	0.7	-0.16	0.35	-0.18	0.64	-0.01	-0.4	-0.24	0.36	0.58	0.43	-0.38	0.09		0.72
Other Assets	0.58	0.17	0.38	0.48	-0.13	0.02	0.34	0.56	0.34	0.74	0.37	0.47	-0.05	0.47	0.01	0.61	-0.14	-0.15	0.09	0.36	0.3	0.21	-0.69	-0.03	0.72

Click cells to compare fundamentals

Neurotech International Account Relationship Matchups

Neurotech International balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	652.7K	80.8K	5.0M	2.0M	5.3M	12.2M
Other Current Liab	75.0K	8.4K	25.4K	72.9K	57.8K	35.9K
Total Current Liabilities	355.3K	727.1K	349.4K	593.0K	1.3M	314.7K
Total Stockholder Equity	297.4K	(646.3K)	3.9M	1.4M	4.0M	11.9M
Net Tangible Assets	297.4K	(646.3K)	3.9M	1.4M	4.0M	487.1K
Retained Earnings	(16.2M)	(17.9M)	(25.3M)	(28.7M)	(36.4M)	(41.6M)
Accounts Payable	154.2K	664.5K	324.0K	520.1K	1.3M	278.8K
Cash	474.7K	12.4K	4.8M	1.9M	3.0M	11.6M
Net Receivables	168.8K	59.3K	142.9K	99.5K	257.6K	318.1K
Inventory	71.0K	2.5K	2.4K	7.2K	7.8K	34.6K
Other Current Assets	9.3K	9.1K	35.7K	18.2K	16.8K	269.6K
Other Stockholder Equity	1.4M	1.0	(416.5K)	4.3M	65.5K	(144.3K)
Total Liab	355.3K	727.1K	1.1M	593.0K	1.3M	314.7K
Total Current Assets	652.7K	80.8K	5.0M	2.0M	5.3M	12.2M
Common Stock	15.1M	15.5M	25.8M	25.8M	34.4M	46.7M
Property Plant Equipment	374.2K	0.0	6.8K	2.6K	870.0	401.5K
Net Debt	41.8K	(4.8M)	(1.9M)	(3.0M)	(11.6M)	(11.0M)
Cash And Short Term Investments	12.4K	4.8M	1.9M	5.0M	11.6M	12.2M
Common Stock Shares Outstanding	154.6M	492.6M	697.3M	798.8M	912.0M	957.6M
Liabilities And Stockholders Equity	80.8K	5.0M	2.0M	5.3M	12.2M	12.8M
Accumulated Other Comprehensive Income	1.8M	3.4M	4.3M	6.0M	6.7M	7.1M
Net Invested Capital	(599.7K)	3.9M	1.4M	4.0M	11.9M	12.5M
Net Working Capital	(646.3K)	4.7M	1.4M	4.0M	11.9M	12.5M
Capital Stock	15.5M	25.8M	25.8M	34.4M	46.7M	29.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Neurotech Stock Analysis

When running Neurotech International's price analysis, check to measure Neurotech International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurotech International is operating at the current time. Most of Neurotech International's value examination focuses on studying past and present price action to predict the probability of Neurotech International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurotech International's price. Additionally, you may evaluate how the addition of Neurotech International to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC